Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity

v3.23.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Conversion of Convertible Debt
Common Stock
Common Stock
Conversion of Convertible Debt
Additional Paid-in Capital
Additional Paid-in Capital
Conversion of Convertible Debt
Stockholders’ Accumulated Deficit
Balance, at beginning of period at Dec. 31, 2021 $ 25,212   $ 0   $ 206,776   $ (181,564)
Balance, at beginning of period (in shares) at Dec. 31, 2021     3,753,132        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options 6       6    
Exercise of stock options (in shares)     1,222        
Vesting of restricted stock units, net of taxes (in shares)     3,321        
Stock-based compensation expense 972       972    
Net income (loss) (10,756)           (10,756)
Balance, at end of period at Mar. 31, 2022 15,434   $ 0   207,754   (192,320)
Balance, at end of period (in shares) at Mar. 31, 2022     3,757,675        
Balance, at beginning of period at Dec. 31, 2022 54,558   $ 1   220,951   (166,394)
Balance, at beginning of period (in shares) at Dec. 31, 2022     4,492,157        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options $ 7       7    
Exercise of stock options (in shares) 6,744   6,744        
Vesting of restricted stock units, net of taxes $ (2)       (2)    
Vesting of restricted stock units, net of taxes (in shares)     5,604        
Stock-based compensation expense 1,442       1,442    
Conversion of convertible notes payable   $ 8,567   $ 0   $ 8,567  
Conversion of convertible notes payable (in shares)       1,147,943      
Net income (loss) (23,435)           (23,435)
Balance, at end of period at Mar. 31, 2023 $ 41,137   $ 1   $ 230,965   $ (189,829)
Balance, at end of period (in shares) at Mar. 31, 2023     5,652,448